Company Profile

Novexin was founded by two biochemical engineers from University of Cambridge, Dr Daniel Jones and Dr Heikki Lanckriet.

They recognised the severe problems which exist in producing high quality protein products and invented a radical new approach to circumvent the problems.

Novexin has rapidly established itself as a major provider of innovative technologies and products for protein handling and analysis to customers in the life sciences sector worldwide. Its products, involving carbohydrate derivatives, are covered by several patent applications owned by Novexin.

The development of the company has been funded by private equity capital and has been supported by substantial research and development grants from the UK’s Department of Trade and Industry.